NCT01526746View on ClinicalTrials.gov

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Renal Impairment
Interventions
DRUG

Tasimelteon

20mg capsule, once

DRUG

Tasimelteon

20mg, once

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Inc., Miami

Unknown

DaVita Clinical Research, Minneapolis

Sponsors
All Listed Sponsors
lead

Vanda Pharmaceuticals

INDUSTRY